1. Armitage JO, Antman KH (1992) High-dose cancer therapy. Pharmacology, hematopoietins, stem cells. Williams and Wilkins, Baltimore
2. Peters WP, Eder JP, Henner WD, Bast RC Jr, Schnipper L, Frei E III (1985) Novel toxicities associated with high-dose combination alkylating agents and autologous bone marrow support. In: Dicke KA, Spitzer G, Zander AR (eds) Autologous bone marrow transplantation. Proceedings of the first international symposium. University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas
3. Skipper HE (1979) Combination therapy: some concepts and results. Cancer Res 17:215?257
4. Cancer and Leukemia Group B (1990) Protocol 9082, Southwest Oncology Group trial 9114, a randomized comparative study of high dose cyclophosphamide, cisplatin, and BCNU (CPA/cDDP/BCNU) and autologous bone marrow support versus standard dose CPA/cDDP/BCNU as consolidation to adjuvant CAF for patients with operable stage II or stage III breast cancer involving >10 axillary lymph nodes, phase III. NCI
5. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73?80